Fig. 2From: Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome SurveyProportion of attacks treated with 1, 2, or ≥3 injections of icatibant and C1-inhibitor (C1-INH) rescue medication(s) in patients who received or did not receive long-term prophylaxis (LTP)Back to article page